Are rotavirus vaccines a good investment for middle-income countries?
Middle-income countries not eligible for support from Gavi, the Vaccine Alliance, have been slow to introduce rotavirus vaccines, largely due to cost concerns. A PATH analysis shows that, in most cases, rotavirus vaccination is likely to be highly cost-effective and beneficial for these countries.
Brief is available in English, French, Russian, and Spanish.
Publication date: July 2021